Clearmind Medicine

Clearmind is focusing on developing novel psychedelic compounds primarily for the treatment of alcohol use disorder.


Clearmind has developed 5-Methoxy-2-aminoindane (MEAI), a psychoactive compound that exerts a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages. At present, Clearmind holds 6 patents with a further 5 pending.

Clearmind Medicine received $6.255 million following a round of funding that closed in June 2021. Shares were priced at CAD 1.25.

Company Information

Clearmind Medicine Website

July, 2017


B2B B2C Pharmaceutical Biotech Drug Discovery

Topics of Interest
Alcohol Use Disorder

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships


HQ / Office 101-1220 W 6th Ave, Vancouver, BC V6H 1A4, Canada